Effects of entecavir combined with compound glycyrrhizin on liver function and serum levels of HA, IV-C and PC-III in patients with hepatitis B cirrhosis

Abstract

Objective To investigate the effects of entecavir combined with compound glycyrrhizin on liver function and serum levels of hyaluronic acid (HA), type Ⅳ collagen (Ⅳ-C) and type Ⅲ procollagen (PC-Ⅲ) in patients with hepatitis B cirrhosis. Methods Eighty-six patients with hepatitis B cirrhosis admitted to the Third People’s Hospital from January 2017 to December 2018 were selected for the study. And they were divided into observation group and control group by random number table method, with 43 cases in each group. Patients in the control group were given entecavir, and patients in the observation group were given combined therapy of compound glycyrrhizin and entecavir. The therapeutic effects of the two groups were compared. The effects of therapy on liver function, serum fibrosis and immune function indexes were analyzed, and the occurrence of adverse reactions was recorded. Results The effective rate of treatment in the observation group was 95.35% (41/43), significantly higher than the 79.07% (34/43) in the control group (P<0.05). After treatment, the levels of albumin (ALB) in the two groups were significantly increased, while the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin (TBiL) were significantly decreased in the two groups (P<0.05). After treatment, the level of ALB in observation group was significantly higher than that in control group, while the levels of AST, ALT and TBiL were significantly lower than those in control group (P<0.05). After treatment, the levels of laminin (LN), HA, PC-Ⅲ and Ⅳ-C were significantly decreased, and the levels of LN, HA, PC-Ⅲ and Ⅳ-C in observation group were significantly lower than those in control group (P<0.05). After treatment, the cluster of differentiation (CD)4+ and CD4+ /CD8+ were significantly increased, while the CD8+ was significantly decreased in both groups (P<0.05). Moreover, the CD4+ and CD4+ /CD8+ in the observation group were significantly higher than those in the control group after treatment, while the CD8+ was significantly lower than that in control group (P<0.05). There were no adverse reactions in neither group. Conclusions Entecavir combined with compound glycyrrhizin has exact efficacy in the treatment of patients with hepatitis B cirrhosis, and it can significantly improve the liver function and immune function, and relieve liver fibrosis, with high safety . Key words: Entecavir; Compound glycyrrhizin; Hepatitis B cirrhosis; Liver function; Hyaluronic acid; Type Ⅳ collagen; Type Ⅲ procollagen